Eugia Pharma gets USFDA nod for posaconazole injection, 300 mg/16.7 mL, single-dose vial EP News Bureau Dec 27, 2023 The approved product has an estimated market size of $25.4 million for the twelve months ending October 2023, according to IQVIA
Markets for GvHD in five APAC markets to grow at 8.2 per cent CAGR in 10 years: GlobalData EP News Bureau Aug 27, 2020 The impact of approved therapies replacing generic off-label treatments will be the main driver of growth in the 5GM GvHD market
Global GVHD treatment market will thrive, reaching $545 million by 2023 Usha Sharma Dec 7, 2015 The report also states that Roche’s Rituxan has emerged as the most clinically and commercially attractive therapy that is used in…
